KEY POINTS
- This prospective, open-label, multicenter phase II trial from the Kyoto Radiation Oncology Study Group enrolled 55 patients with locally advanced rectal adenocarcinoma at seven Japanese hospitals between October 2022 and February 2024. The study used a historically controlled, single-arm design to test whether modern bowel-sparing IMRT could reduce grade ≥2 acute diarrhea compared with a 26% historical rate from earlier three-dimensional conformal chemoradiotherapy studies. Forty-eight patients had stage III disease, and 25 (45%) had MRI-positive circumferential resection margins.
- Treatment combined capecitabine with IMRT delivering 45 Gy in 25 fractions to the primary and elective pelvic nodal volumes, with an optional 5.4-Gy boost in three fractions to gross disease. Capecitabine was prescribed at 1,650 mg/m²/day in two divided doses on irradiation days. Small- and large-bowel dose constraints were prospectively defined, including an acceptable small-bowel V15Gy <200 cm³. Central planning review and institutional dummy runs were completed before patient enrollment.
- The primary endpoint was met with only four grade ≥2 diarrhea events among 55 patients (7.3%). The corresponding 90% CI was 2.5–15.9%, below the prespecified 26% historical benchmark (p<0.001). A conservative sensitivity analysis counting two patients with incomplete scheduled assessments as events produced 10.9% (6/55), with an upper 90% confidence limit of 20.4%, still meeting the protocol criterion. These results do not constitute a randomized demonstration of superiority over 3DCRT.
- Small-bowel low- and intermediate-dose exposure was substantially constrained. Median small-bowel V15Gy was 85 cm³ (IQR 47–105), while median V5Gy, V30Gy, and V45Gy were 213, 32, and 0 cm³, respectively. The stringent planning targets were achieved in 73% for V15Gy, 75% for V30Gy, and 85% for V45Gy, but only 47% for V5Gy. Overall PTV D95% met the acceptable planning objective in 48/55 cases (87%), reflecting practical compromises between bowel sparing and target coverage.
- Protocol treatment completion was high, although other acute pelvic toxicities occurred. Fifty-four of 55 patients (98.2%) completed the prescribed chemoradiotherapy, with capecitabine dose reductions in 7.3%. Grade ≥2 proctitis occurred in 9.1%, anal pain in 16.4%, and perianal dermatitis in 7.3%. One patient discontinued treatment after ten fractions because of worsening pre-existing cardiac and renal dysfunction.
- Surgical and pathological outcomes did not reveal an obvious early safety signal, but response rates were modest. Fifty patients (90.9%) underwent radical surgery after a median interval of 54 days. Pathological complete response occurred in 3/50 patients (6.0%), while 44/50 (88.0%) achieved a pathological circumferential margin greater than 1 mm. Grade ≥2 postoperative complications occurred in 14.0%, including 4.0% grade ≥3 complications. Five patients did not undergo surgery because of progression, death, or a decision for nonoperative management.
- Oncological follow-up remains immature. After median follow-up of 14 months, 12-month locoregional progression-free survival was 95.0% and overall survival 98.2%. The primary toxicity assessment also ended at the earliest of surgery, additional chemotherapy, or 90 days after chemoradiotherapy initiation, limiting conclusions about later gastrointestinal morbidity. The absence of concurrent randomization and contemporary total neoadjuvant therapy comparators prevents attribution of the low diarrhea rate exclusively to IMRT.
CLINICAL TAKEAWAY
Modern IMRT with prospectively defined bowel constraints was associated with a low incidence of clinically significant acute diarrhea during neoadjuvant rectal chemoradiotherapy, meeting the study's historical-control benchmark. The findings support careful low-dose bowel optimization and prospective planning quality assurance, but do not establish comparative superiority over contemporary 3DCRT or alternative neoadjuvant strategies. Longer follow-up is needed to determine whether reduced acute toxicity is maintained without compromising oncological outcomes.
SOURCE
International Journal of Radiation Oncology, Biology, Physics